## Jia Yu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1601388/publications.pdf

Version: 2024-02-01

31	1,284	18	33
papers	citations	h-index	g-index
33	33	33	2350 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Molecular Cell, 2019, 74, 1215-1226.e4.	9.7	144
2	DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. Journal of Clinical Investigation, 2018, 128, 2376-2388.	8.2	134
3	CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nature Communications, 2017, 8, 13923.	12.8	119
4	UFL1 promotes histone H4 ufmylation and ATM activation. Nature Communications, 2019, 10, 1242.	12.8	104
5	Regulation of Serine-Threonine Kinase Akt Activation by NAD + -Dependent Deacetylase SIRT7. Cell Reports, 2017, 18, 1229-1240.	6.4	84
6	L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nature Cell Biology, 2018, 20, 455-464.	10.3	84
7	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. Journal of the National Cancer Institute, 2017, 109, .	<b>6.</b> 3	61
8	ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2018, 17, 2462-2472.	4.1	59
9	Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Research, 2020, 30, 590-601.	12.0	58
10	DBC1 Functions as a Tumor Suppressor by Regulating p53 Stability. Cell Reports, 2015, 10, 1324-1334.	6.4	56
11	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Research, 2017, 19, 130.	<b>5.</b> O	53
12	Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation. EMBO Reports, 2018, 19, .	<b>4.</b> 5	43
13	<i>CYP2C9</i> and <i>CYP2C19</i> : Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants. Clinical and Translational Science, 2020, 13, 727-742.	3.1	33
14	STK38 promotes ATM activation by acting as a reader of histone H4 ufmylation. Science Advances, 2020, 6, eaax8214.	10.3	32
15	TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castrationâ€Resistant Prostate Cancer. Clinical Pharmacology and Therapeutics, 2018, 104, 201-210.	4.7	27
16	Ubiquitin and ubiquitin-like molecules in DNA double strand break repair. Cell and Bioscience, 2020, 10, 13.	4.8	24
17	Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion. Breast Cancer Research, 2017, 19, 95.	5.0	22
18	Targeting DNA methylation for treating triple-negative breast cancer. Pharmacogenomics, 2019, 20, 1151-1157.	1.3	21

#	Article	IF	Citations
19	ZNF506-dependent positive feedback loop regulates H2AX signaling after DNA damage. Nature Communications, 2018, 9, 2736.	12.8	17
20	The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer. Cancer & Metabolism, 2019, $7$ , $1$ .	5.0	17
21	ERICH3: vesicular association and antidepressant treatment response. Molecular Psychiatry, 2021, 26, 2415-2428.	7.9	17
22	Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Clinical Pharmacology and Therapeutics, 2020, 107, 662-670.	4.7	11
23	Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. Oncotarget, 2019, 10, 3924-3930.	1.8	11
24	Patient-specific multi-omics models and the application in personalized combination therapy. Future Oncology, 2020, 16, 1737-1750.	2.4	10
25	PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient. JCO Clinical Cancer Informatics, 2018, 2, 1-11.	2.1	8
26	NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110278.	3.2	8
27	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). Clinical Cancer Research, 2021, 27, 4696-4699.	7.0	7
28	Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castrationâ€Resistant Prostate Cancer. Clinical Pharmacology and Therapeutics, 2022, 111, 1296-1306.	4.7	6
29	Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX). Npj Breast Cancer, 2021, 7, 79.	5.2	5
30	Tumor protein <scp>D52</scp> ( <scp>TPD52</scp> ) affects cancer cell metabolism by negatively regulating <scp>AMPK</scp> . Cancer Medicine, 2023, 12, 488-499.	2.8	3
31	A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. Clinical Cancer Research, 2020, 26, 159-170.	7.0	2